Evidence map›Paper›PMID 41382084›Full record

ArticleJournal of translational medicine2025

Machine learning-based identification of kbhb-affected tumor cell subsets as prognostic and therapeutic targets in breast cancer.

Quan Yuan, Yupeng Sha, Rongjie Ye, Hao Yu, Lin Ni, Jiguang Han, Lin Deng

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Quan YuanDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150000, China.
Yupeng ShaDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150000, China.
Rongjie YeQuanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian, 362000, China.
Hao YuSchool of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, 361000, China.
Lin NiDepartment of General Surgery, The 900th Hospital of Joint Logistic Support Force, Fuzhou, 350025, China.
Jiguang HanDepartment of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150000, China. han_jg112@163.com.
Lin DengDepartment of General Surgery, The 900th Hospital of Joint Logistic Support Force, Fuzhou, 350025, China. pywdenglin@163.com.ORCID 0000-0001-6344-3552

Funding

China Health & Medical Development Foundation No. chmdf2025-xrkt04-03the China Primary Health Care Foundation No. cphcf-2023-017the Haiyan Science Foundation No. JJZD2021-02the Intra-Hospital Project of 900TH Hospital of The Joint Logistics Support Force No. 2023QN08the Wu Jie Ping Medical Foundation No. 320.6750.18215
6 · The paper itself

Abstract

backgroundBreast cancer heterogeneity complicates prognosis and treatment. Metabolic reprogramming, particularly lysine beta-hydroxybutyrylation (Kbhb) driven by ketone bodies, influences the tumor microenvironment. However, the impact of Kbhb on specific breast cancer subpopulations remains unclear. This study aims to identify Kbhb-affected tumor cell subsets and evaluate their prognostic potential.

methodsWe integrated multi-omics data from TCGA, GEO, single-cell RNA sequencing, and spatial transcriptomics. After identifying breast cancer subpopulations influenced by Kbhb-associated genes, we validated the functional role of key genes via molecular experiments. A machine learning-based prognostic model was developed using 101 algorithm combinations.

resultsWe identified a tumor cell subset susceptible to Kbhb-related metabolic changes, significantly correlating with patient prognosis. SCGB2A2 overexpression reduced invasion, metastasis, and stemness. A prognostic score derived from Kbhb-affected cell markers accurately predicted patient outcomes and immunotherapy response.

conclusionsKbhb influences breast cancer heterogeneity, with SCGB2A2 + neoplastic cells serving as valuable prognostic indicators. Targeting these cells may improve therapeutic outcomes. Our model also supports machine learning-guided drug discovery for metabolically vulnerable subpopulations.

Indexed as

Breast NeoplasmsMachine LearningMolecular Targeted TherapyFemaleGene Expression Regulation, NeoplasticHumansPrognosis

Identifiers

PMID41382084
PMCPMC12802299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.